Cardinal Health Inc.
CAHBusiness Model
source: coverage-next-full | ticker: CAH | step: "01" | created: 2026-05-29
Step 01 — Business Overview: Cardinal Health Inc. (CAH)
Company Snapshot
Cardinal Health, Inc. (NYSE: CAH) is a global, integrated healthcare services and products company headquartered in Dublin, Ohio. With over $220 billion in annual revenue, it is one of the largest companies in the United States by top-line sales, though net income margins are razor-thin due to the low-margin nature of pharmaceutical distribution.
The company serves as a critical intermediary in the US healthcare supply chain — connecting pharmaceutical manufacturers with the pharmacies, hospitals, health systems, and specialty care providers that ultimately dispense drugs and medical products to patients.
CEO: Jason Hollar
Jason Hollar became Chief Executive Officer in August 2022, having previously served as Chief Financial Officer. He succeeded Mike Kaufmann. Hollar's tenure has been defined by:
- Managing the opioid settlement ($6.4B commitment) without financial distress
- Executing a Medical segment operational turnaround (margin recovery from negative territory in FY2022–2023)
- Accelerating the share repurchase program
- Evaluating strategic alternatives for nuclear pharmacy and specialty assets
Two Reportable Segments
1. Pharmaceutical and Specialty Solutions
The dominant revenue driver, generating approximately $210–220B in annual revenue. Cardinal Health is the third-largest pharmaceutical distributor in the US, behind McKesson and Cencora.
Core distribution business:
- Distributes branded and generic pharmaceuticals from 300+ manufacturers to approximately 29,000 pharmacy customer locations
- Serves retail pharmacies (CVS, Walgreens, independent pharmacies), mail-order pharmacies, hospitals, and health systems
- Revenue driven primarily by branded drug price inflation (pass-through) and generic volume
Specialty Solutions:
- Serves specialty physicians (oncologists, rheumatologists, neurologists) and specialty pharmacies
- Distributes high-cost specialty drugs (biologics, oncology agents, immunology drugs)
- Provides third-party logistics (3PL) services for specialty manufacturers
- Growing component of the segment — specialty drugs carry slightly better margins than broad commodity distribution
Nuclear & Precision Health Solutions:
- Operates the largest commercial nuclear pharmacy network in the US (~170 sites)
- Compounds and delivers radiopharmaceuticals for diagnostics (PET scans, SPECT scans) and targeted radionuclide therapy
- Unique asset with higher barriers to entry, better margins, and growing demand driven by Pluvicto-type therapies
- Sometimes discussed as a separate strategic asset
2. Global Medical Products and Distribution (GMPD / Medical Segment)
Approximately $15–16B annual revenue with operating margins targeting 2–3%+ range.
Distribution:
- Distributes branded and Cardinal Health-owned medical products to hospitals, surgery centers, laboratories
- Products include surgical supplies, PPE, exam gloves, procedure trays, lab consumables
Manufacturing:
- Manufactures Cardinal Health brand products (Presource procedure kits, surgical drapes/gowns, exam gloves, wound care)
- Manufacturing operations in the US, Ireland, Mexico, and Asia
Turnaround context:
- Medical segment suffered significant margin pressure in FY2022–FY2023 due to elevated raw material costs (exam gloves, resins), supply chain disruptions, and unfavorable long-term contracts
- Management executed cost reduction program, SKU rationalization, and renegotiated contracts
- Segment returned to positive operating income in FY2024; management targeting mid-single-digit margins over medium term
Revenue Scale and Mix
| Metric | Approx. Figure |
|---|---|
| Total Revenue | ~$220–230B annually |
| Pharma Segment Revenue | ~$205–215B (>93% of total) |
| Medical Segment Revenue | ~$15–16B (<7% of total) |
| Pharma Operating Margin | ~0.4–0.6% |
| Medical Operating Margin | ~1.5–3.0% (in recovery) |
| Consolidated Operating Margin | ~0.5–0.6% |
How CAH Makes Money
Cardinal Health's economics are fundamentally different from most companies. Despite $220B+ in revenue, GAAP operating income is typically $1.5–2.5B. The real profitability measure is non-GAAP adjusted operating earnings and free cash flow.
Key earning mechanisms:
- Buy-side leverage: Negotiating manufacturer rebates, allowances, and distribution fees
- Generic sourcing scale: Red Oak Sourcing LLC (50/50 JV with CVS Health) — largest generic drug sourcing entity in the US
- Sell-side fees: Distribution service agreements (DSAs) with pharmacy customers
- Working capital float: Hold inventory briefly; pay manufacturers 30–45 days after receipt; collect from pharmacies 7–15 days — positive working capital cycle generates float
Red Oak Sourcing JV
A critical competitive asset: Cardinal Health's 50/50 joint venture with CVS Health for generic drug purchasing. Red Oak is the largest generic drug purchasing organization in the US, giving CAH substantial buy-side leverage on generic sourcing costs. This JV is a structural moat that is not easily replicated.
Divestiture History (2020–2025)
| Asset | Status | Notes |
|---|---|---|
| Cordis (vascular devices) | Divested 2021 | ~$927M |
| at-Home Solutions | Divested 2023 | Home health supply; contributed to Medline distribution deal |
| China JV (Cardinal Health China) | Partial divestiture ~2022 | Reduced international exposure |
| Specialty distribution assets | Strategic review ongoing | Some non-core assets exited |
Employees and Operations
- ~44,000 employees globally
- 25+ pharmaceutical distribution centers across the US
- ~170 nuclear pharmacy compounding/delivery sites
- Manufacturing facilities in US, Ireland, Mexico, Malaysia, Puerto Rico
Investment Characteristics
Cardinal Health presents as a low-growth, high-cash-return, defensive healthcare holding:
- Revenue grows with pharmaceutical price inflation + volume (GDP+ nominal)
- Earnings growth primarily from EPS expansion via buybacks and Medical segment margin recovery
- Highly predictable cash flows (essential healthcare infrastructure)
- Offset by opioid settlement payments ($6.4B over 18 years) and modest organic growth
Financial Snapshot
source: coverage-next-full | ticker: CAH | step: "04" | created: 2026-05-29
Step 04 — Financial Snapshot: Cardinal Health (CAH)
Important Notes on Financial Reporting
- Fiscal Year Convention: CAH FY ends June 30. FY2024 = July 2023 – June 2024.
- GAAP vs. Non-GAAP: Cardinal Health's management and investor community focus on non-GAAP (adjusted) metrics that exclude opioid litigation charges, amortization of intangibles, restructuring, and other one-time items. Both are presented below.
- Divestiture effects: The sale of at-Home Solutions in FY2023 and other divestitures affect comparability; FY2022 and FY2023 revenue bases are not fully comparable to FY2024.
- GAAP operating income is heavily impacted by opioid litigation accruals in FY2022 and FY2023.
Income Statement Summary (FY2022–FY2024, Fiscal Year Ended June 30)
| Metric | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Total Revenue | ~$181B | ~$205B | ~$227B |
| Gross Profit | ~$4.8B | ~$5.4B | ~$6.2B |
| Gross Margin | ~2.6% | ~2.6% | ~2.7% |
| GAAP Operating Income | ~($1.0B) | ~$0.5B | ~$2.1B |
| Non-GAAP (Adj.) Operating Income | ~$1.9B | ~$2.1B | ~$2.4B |
| Non-GAAP Adj. Operating Margin | ~1.0% | ~1.0% | ~1.1% |
| GAAP Net Income (Loss) | ~($932M) | ~$237M | ~$1.6B |
| Non-GAAP Adj. EPS (diluted) | ~$5.24 | ~$6.72 | ~$7.85 |
| GAAP EPS (diluted) | ~($3.37) | ~$0.87 | ~$5.82 |
Key observations:
- Revenue growth of ~10–12% annually driven by pharmaceutical price inflation + specialty volume + GLP-1 drugs
- FY2022 GAAP figures reflect large opioid litigation charges (~$1.9B pre-tax)
- Non-GAAP adjusted EPS growth ~20% from FY2022 to FY2024 reflects Medical turnaround, buybacks, and operating leverage
- Non-GAAP Adj. EPS is the primary management incentive and market valuation metric
Segment Operating Income
| Segment | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Pharma & Specialty (Non-GAAP Adj. OI) | ~$1.5B | ~$1.7B | ~$2.0B |
| Medical / GMPD (Non-GAAP Adj. OI) | ~$40M | ~$85M | ~$280M |
| Corporate / Other | ~($350M) | ~($330M) | ~($310M) |
| Total Non-GAAP Adj. OI | ~$1.9B | ~$2.1B | ~$2.4B |
Medical segment recovery is the key earnings growth driver: from ~$40M to ~$280M adjusted operating income in two years.
Free Cash Flow
| Metric | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Operating Cash Flow | ~$1.9B | ~$2.2B | ~$2.6B |
| Capital Expenditures | ~($550M) | ~($450M) | ~($400M) |
| Free Cash Flow | ~$1.4B | ~$1.8B | ~$2.2B |
| FCF / Non-GAAP Adj. Net Income | ~100–110% | ~95–105% | ~95–105% |
FCF consistently approximates adjusted earnings. The working capital model (positive float) supports cash generation.
Note: FY2022 and FY2023 FCF benefited from opioid settlement payments being classified differently (below operating income per GAAP). Actual economic cash cost includes ~$500–600M/year in opioid settlement payments.
Key Non-GAAP Adjusted EPS Progression
| FY | Adj. EPS (Diluted) | YoY Growth | Notes |
|---|---|---|---|
| FY2020 | ~$5.00 | — | Pre-opioid settlement accruals |
| FY2021 | ~$5.73 | +15% | COVID PPE boost |
| FY2022 | ~$5.24 | -9% | Medical margin collapse begins |
| FY2023 | ~$6.72 | +28% | Medical recovery + pharma growth |
| FY2024 | ~$7.85 | +17% | Continued turnaround + buybacks |
| FY2025E | ~$8.50–9.00 | ~8–14% | Buy-side consensus estimates |
Adjusted EPS Bridge: Key Drivers
The adjusted EPS growth from FY2022 to FY2024 (~50% total) reflects:
- Medical segment turnaround: ~$0.85 per share impact (from $40M to $280M OI, ~247M shares)
- Pharmaceutical segment growth: Specialty volume + branded price inflation + GLP-1 tailwind (~$0.50/share)
- Share count reduction: Buybacks reduced shares from ~270M (FY2022) to ~235–240M (FY2024) — ~$0.40/share EPS accretion
- Interest expense changes: Net interest income on higher cash balances post-divestitures
Balance Sheet Summary (as of June 30, 2024)
| Metric | Approx. |
|---|---|
| Cash & Equivalents | ~$4.0–4.5B |
| Total Assets | ~$45–48B |
| Total Debt | ~$5.5–6.0B |
| Net Debt | ~$1.5–2.0B |
| Opioid Settlement Liabilities (remaining) | ~$5.5–6.0B (long-term; $6.4B over 18 years, some paid) |
| Shareholders' Equity | Negative (buybacks exceed book equity) |
Note: CAH reports negative book equity due to aggressive share repurchases eroding retained earnings and paid-in capital. This is common for companies with capital-light, high-cash-flow business models (similar to McDonald's, AbbVie historically). The negative equity does not indicate financial distress.
Shareholder Returns (FY2022–FY2024)
| Metric | FY2022 | FY2023 | FY2024 |
|---|---|---|---|
| Share Repurchases | ~$1.2B | ~$2.0B | ~$2.4B |
| Dividends Paid | ~$500M | ~$500M | ~$520M |
| Total Capital Returned | ~$1.7B | ~$2.5B | ~$2.9B |
| vs. Free Cash Flow | ~120% | ~140% | ~130% |
CAH has returned more than 100% of FCF to shareholders, funded partly by divestiture proceeds.
Key Financial Ratios (FY2024)
| Ratio | Value | Notes |
|---|---|---|
| Non-GAAP P/E (at ~$115 stock price) | ~14–15x | On ~$7.85 adj. EPS |
| EV/EBITDA | ~10–12x | Enterprise value ~$28–30B |
| FCF Yield | ~7–8% | On ~$27B market cap |
| Dividend Yield | ~2.1% | At ~$115 stock price |
| Non-GAAP ROE | Meaningfully positive (on adjusted basis) | Book equity negative per GAAP |
| Net Debt / EBITDA | ~0.5–0.7x | Excluding opioid liabilities |
Opioid Settlement: Financial Accounting
| Item | Detail |
|---|---|
| Total Committed Amount | ~$6.4B over ~18 years (through ~2038) |
| Annual Payment | ~$350–400M/year on average |
| Accounting Treatment | Liability recorded on balance sheet; payments classified as operating activities (GAAP) |
| Non-GAAP Exclusion | Opioid-related charges excluded from adjusted operating income and adjusted EPS |
| Tax Effect | Payments are deductible; effective after-tax cost ~$260–320M/year |
This is a significant but known, scheduled liability. The market has largely priced it in, and CAH's free cash flow is sufficient to service payments without financial stress.
Recent Catalysts
source: coverage-next-full | ticker: CAH | step: "12" | created: 2026-05-29
Step 12 — Catalysts & Variant Analysis: Cardinal Health (CAH)
Near-Term Catalysts (0–12 Months)
1. Medical Segment Margin Progress
The most watched metric quarter-to-quarter. Any quarter where Medical adj. operating margin exceeds ~2.0–2.5% will re-rate the stock. Management's FY2025 guidance of ~$300–350M in Medical adj. OI (vs. ~$280M in FY2024) implies ~7–25% growth. Upside to these targets would be a positive catalyst.
2. FY2025 Guidance Update / Beat
With non-GAAP adj. EPS guidance of ~$8.00–8.50 for FY2025, any upward revision (driven by specialty volume, Medical recovery, or buybacks) would push consensus higher and likely re-rate the stock. Q3 FY2025 earnings (reported ~May 2025) and Q4 FY2025 (reported ~August 2025) are the key reporting events.
3. Nuclear Pharmacy Strategic Announcement
The market has been waiting for clarity on the nuclear pharmacy business. Options discussed include:
- Standalone spinoff (could unlock $6–9B in value by applying a specialty healthcare multiple)
- JV or partnership with a radiopharmaceutical manufacturer
- Continued operation within CAH with improved disclosure Any announcement providing clarity would be a near-term positive catalyst.
4. CVS Contract Renewal
The CVS distribution agreement is periodically renewed. A successful multi-year renewal (reported publicly or implied by stable revenue guidance) removes a significant overhang and is modestly positive. Red Oak JV renewal (tied to distribution) would be similarly positive.
5. GLP-1 Volume Acceleration
If GLP-1 prescriptions (Ozempic, Wegovy, Mounjaro, Zepbound) continue to grow at 30–50%+ annually, CAH's Pharmaceutical segment revenue and fee income grow correspondingly. This is an ongoing structural tailwind — each quarter of strong GLP-1 data confirms the thesis.
Medium-Term Catalysts (12–36 Months)
6. New Radiopharmaceutical Product Launches
Multiple new radiopharmaceutical products are approaching commercialization:
- Alzheimer's amyloid/tau PET tracers: Growing diagnostic demand as anti-amyloid therapies (Leqembi, Kisunla) expand — requires amyloid PET confirmation, distributed through nuclear pharmacies
- Next-generation PSMA therapies: Pipeline drugs beyond Pluvicto from Novartis and others
- Actinium-based therapies: Higher potency, potentially larger market than lutetium therapies
- RYZ101, iQS-001, and other pipeline agents: ~10–15 new radiopharmaceutical approvals expected 2025–2028
CAH's nuclear pharmacy network is the natural distribution partner for all these launches.
7. Share Count Reduction Compounding
At the current pace (~$2B+ in buybacks/year vs. ~$28B market cap), CAH retires ~7–8% of shares annually. Over 3 years, this represents ~20% fewer shares outstanding, driving ~25% adj. EPS growth even if operating earnings hold flat. This mechanical EPS growth provides a durable return in a low-growth environment.
8. M&A in Nuclear or Specialty
An accretive acquisition in the nuclear pharmacy or specialty distribution space could accelerate growth. Potential targets: radiopharmaceutical logistics specialists, specialty distribution bolt-ons, or nuclear pharmacy networks outside the US.
Structural Thesis: GLP-1 + Specialty + Nuclear as Three-Layer Growth
The most compelling medium-term thesis is that CAH has three simultaneously accelerating growth drivers that the market is not fully pricing in:
- GLP-1 volumes (100M+ potential patients; ~$150–200B eventual market)
- Specialty pharmaceutical growth (10–15%/year sector growth)
- Nuclear pharmacy expansion (theranostic medicine secular growth)
All three benefit Cardinal Health disproportionately relative to its historical baseline.
Bull Case
- GLP-1 drug distribution volumes continue growing at 25–40% annually, adding ~$0.50–1.00/share to annual adj. EPS over 3 years through volume-driven fee income expansion
- Medical segment achieves 3–4% operating margins by FY2027, adding ~$300–400M in adj. OI vs. current run rate, representing ~$1.00–1.30/share additional EPS
- Nuclear pharmacy is spun off or sold at specialty healthcare multiples (
15–20x EBITDA), unlocking $6–9B in value ($25–38/share) that is currently embedded in the stock at distribution multiples
Bear Case
- CVS Health terminates or substantially renegotiates its distribution agreement at contract renewal, reducing Pharmaceutical segment revenue by 20–25% and adj. OI by 30–35%, creating a structural earnings reset and potentially 40–50% stock price decline
- Drug pricing reform expands significantly beyond the IRA's initial scope — Congress enacts mandatory rebate elimination or price caps that restructure distributor economics, compressing fee income by 2–3% on branded drugs and reducing adj. EPS by 15–25%
- Medical segment turnaround stalls at ~1.5–2.0% operating margins due to ongoing GPO pricing pressure and manufacturing cost inflation, eroding management credibility and removing the key near-term earnings growth driver, leading to multiple compression to 11–12x forward adj. EPS
Full Research Available
This primer covers steps 1–3 of 21. The full deep dive includes moat analysis, DCF valuation, bull/bear scenarios, management quality, earnings transcript analysis, competitive positioning, returns on capital, institutional/insider activity, and an investment memo.